Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients

Summary

The primary purpose of this study is to evaluate whether the drug EI-001 can help improve vitiligo symptoms. EI-001 is a novel antibody drug that affects the immune system to decrease uncontrolled inflammation. EI-001 has been investigated in human cell cultures, animal studies, and in a Phase 1 healthy volunteer study. The results so far show that EI-001 is a tolerable and potential new treatment for immune diseases such as vitiligo.

Timeline

Start

2025-12-30

Primary completion

2026-12-31

Completion

2027-09-30

Drugs

Indications